Neuren Pharmaceuticals (ASX:NEU) said its partner Acadia Pharmaceuticals reported first-quarter net sales of $84.6 million in the US for its Rett syndrome drug, Daybue, according to a Thursday Australian bourse filing.
The figure represents an 11% increase from last year, the filing said.
Acadia, the company's partner for the development and commercialization of the drug, retained the net sales guidance for the current year of between $380 million and $405 million for the US market.
The company expects US royalties of AU$62 to AU$67 million for the year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。